GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is conducting a Phase 2 study titled ‘A Phase ...

(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help prevent ...

C HICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic ...

Asian patients with non-cystic fibrosis bronchiectasis had a lower annualized exacerbation rate and less lung function ...

The use of CT scans is moving beyond a simple diagnostic tool for non–cystic fibrosis bronchiectasis to become a practical ...

In bronchiectasis, highly symptomatic patients have a greater risk of exacerbations and may benefit from long-term macrolide treatment.

Panelists discuss how bronchiectasis is more common than previously thought, with growing awareness, research, and specialized centers improving diagnosis and treatment options, though challenges ...

Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic ...

NEW YORK, New York — Despite significant baseline differences, the disease progression and the outcomes at 5 years are similar in those with nontuberculous mycobacteria (NTM) infection relative to ...